Rosiglitazone Glimepiride

Hypoglycemia - If hypoglycemia occurs during up-titration of the dose or while maintained on therapy, a dosage reduction of the sulfonylurea component of rosiglitazone/glimepiride may be considered. 

Pregnancy/Lactation - Rosiglitazone/Glimepiride should not be used during... 

C/ //c/ren - There are no data on the use of rosiglitazone/glimepiride in patients younger than 18 years of age therefore, use of rosiglitazone/glimepiride in pediatric patients is not recommended. 

Special populations - In elderly, debilitated, or malnourished patients, or patients with renal, hepatic, or adrenal insufficiency, the initial dosing, dose increments, and maintenance dosage of rosiglitazone/glimepiride should be conservative to avoid hypoglycemic reactions. 

Therapy with rosiglitazone/glimepiride should not be initiated if the patient exhibits clinical evidence of active liver disease or increased serum transaminase levels (ALT greater than 2.5 x upper limit of normal at start of therapy). Liver enzyme monitoring is recommended in all patients prior to initiation of therapy with rosiglitazone/glimepiride and periodically thereafter. 

AccessMedicine Print Chapter 41. Pancreatic Hormones Antidiabetic Drugs Rosiglitazone plus glimepiride (Avandaryl)... 

If the patient with angina is diabetic, certain considerations apply. Insulin is eminently cardioprotective, as already described, while the sulfonylureas have an unfavorable profile. Probably less selective blockers as glimepiride should be preferred to glibenclamide.146 PPARy agonists such as rosiglitazone have been found to be cardioprotective262- 263 and to have an antiapoptotic effect in hypercholesterolemic rabbits subjected to myocardial ischemia/reperfusion.264... 

Internal standards (as powder) Glimepiride-dg, repaglinide ethyl-dg, rosiglitazone-d (all from Toronto Research Chemical) zomepirac (Sigma). 

---